ANAGENICS Limited

ACN 111 304 119

Appendix 4E (ASX Listing Rule 4.3A)

Appendix 4E Preliminary final report

For the financial year ended 30 June 2026

This Appendix 4E for Anagenics Limited and its subsidiaries (ASX: AN1) for the financial year ended 30 June 2026 is filed with the Australian Securities Exchange (ASX) under ASX Listing Rule 4.3A. This report should be read in conjunction with the Anagenics Limited 2026 Annual Report, and any public announcements made during the year by Anagenics Limited in accordance with the continuous disclosure requirements of the *Corporations Act 2001* and ASX Listing Rules.

Information presented for the previous corresponding period is for the financial year ended 30 June 2025.

Results for announcement to the market

Comparison to previous corresponding periods	Increase/ Decrease	%	Amount
Revenue from ordinary activities	Increase	0.80%	$5,159,679
Net profit from ordinary activities after tax attributable to shareholders	Increase	NM*	308,472
Net profit for the period attributable to shareholders	Increase	NM*	308,472

* Not Meaningful

Refer to the Anagenics Limited 2026 Annual Report for commentary on the above results.

There were no dividends paid, recommended or declared during the current financial period.

There was no change in the gain or loss of control of subsidiaries in the year ended 30 June 2026. None of the subsidiaries applied accounting standards that differ from those used by the consolidated entity. The consolidated entity has no interests in associates or joint ventures.

Net tangible assets per security

	June 2026	June 2025
Net tangible asset backing per ordinary security	0.23 cent	(0.03) cent

The net assets include both right-of-use assets and corresponding lease liabilities.
The number of Anagenics shares on issue as at 30 June 2026 was 985.5 million (2025: 496.3 million).

Results commentary

Additional Appendix 4E disclosure requirements can be found in the Anagenics Limited financial report for the year ended 30 June 2026.

This report is based on the consolidated financial statements of Anagenics Limited, which have been audited by Stannards Audit Pty Ltd, and they have issued an unmodified audit report.

The release of this announcement was authorised by the Board.